The company’s management team will discuss the broader market potential for proton therapy and outline how Advanced Oncotherapy’s LIGHT system could accelerate the adoption of proton therapy as a treatment modality for several different cancer indications.
The team will also discuss how the LIGHT system can potentially be adapted for FLASH delivery of protons, an emerging mode of proton therapy treatment that uses ultra-high dose rates.
Advanced Oncotherapy expects to have a fully operational LIGHT system at Daresbury in Cheshire with beam energy, suitable to support patient treatment, during 2021. The actual treatment of patients, which is expected to occur shortly after this LIGHT machine is fully operational, remains dependent on the company's clinical partner, University Hospital Birmingham.
"At today's presentation, we will reaffirm our view from the interim results that, although there have been headwinds caused as a result of COVID-19 pandemic during 2020, the company has made strong progress and now has all the key high-precision components of the accelerator in place at Daresbury,” said Nicolas Serandour, the chief executive officer of Advanced Oncotherapy in a statement.
“2021 is set to be an exciting year for the company as we expect to have a fully operational LIGHT system with a 230MeV beam, which is the beam energy needed to treat patients. We also expect to sign further commercial agreements for new machines as we progress our robust pipeline of opportunities,” he added.
Investors will be able to access the investor day presentation online.